全球核药龙头大消息

中国基金报
08 Jul

【导读】全球核药龙头大消息!剑指百亿蓝海市场  中国药企核药海外研发迎来里程碑时刻。  在全球结直肠癌肝转移选择性内放射治疗领域大放异彩后,全球核药龙头远大医药(0512.HK)的全球创新核药SIR-Spheres®钇[90Y]微球注射液(易甘泰®),近期又打开了肝细胞癌治疗的大门。  据远大医药7月7日晚公告,基于钇[90Y]微球注射液DOORwaY90临床试验的突破性中期数据成功达到预设的共同...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10